Researchers identify renegade cells that portend relapse in children with leukemia

March 5, 2018, Stanford University Medical Center
A Wright's stained bone marrow aspirate smear from a patient with precursor B-cell acute lymphoblastic leukemia. Credit: VashiDonsk/Wikipedia

Researchers at the Stanford University School of Medicine have developed a technique that allowed them to determine at diagnosis whether children with acute lymphoblastic leukemia would relapse following treatment.

The method, described in a paper publishing online March 5 in Nature Medicine, predicted in the cohort they examined with 85 percent accuracy, a significant improvement from 66 percent accuracy achieved by the current risk stratification method used at diagnosis. The method examines cancer cells one at a time using mass cytometry, a technique developed by Garry Nolan, PhD, professor of microbiology and immunology and a senior author of the study. Using data on the cells' stage of development and signaling behavior, the scientists figured out how to identify a tiny subset of malignant cells that, if present, predisposed a patient to relapse.

Called the Developmentally Dependent Predictor of Relapse, the technique could help identify which patients need a different approach to cancer treatment, and may provide good clues about how to find new drugs to target the deadliest cancer cells, the researchers said.

"We really need to personalize treatment to leukemia patients better than we do now," said graduate student Zinaida Good, the study's co-lead author. "There is a lot of room for improvement here. This study makes a contribution to our ability to stratify patients better and not treat everybody the same way."

Postdoctoral scholar Jolanda Sarno, PhD, is the other lead author.

Pediatric acute lymphoblastic leukemia is the most common childhood cancer, diagnosed in about 3,000 American children per year. The study focused on the most frequently found type of the disease, called B-cell precursor ALL, which occurs when certain take a wrong turn during development and become malignant. Although the majority of cases are cured with existing chemotherapy drugs, 10-20 percent of patients relapse. Among those who relapse, about 40-80 percent die of their disease within five years.

"Acute lymphoblastic leukemia is a very well-characterized cancer that has a robust risk prediction measure already, but the final risk of relapse is usually not known until a few months into treatment, and there are still patients who get missed," said Kara Davis, DO, assistant professor of pediatric hematology and oncology and the other senior author of the study. "And, with existing prediction tools, when we do identify someone as high-risk for relapse, we don't know what it is about their leukemia that raises their risk."

A few really bad apples

Prior research strongly suggested that may be driven by a few treatment-resistant cells that are present from the beginning of the disease. "We wondered, can we identify those cells at the time the patient first presents to clinic, and can we treat patients with a specific therpy to target them?" Davis said.

Using mass cytometry, the researchers tested bone marrow samples taken from 60 ALL patients at the time of their diagnosis. Each patient had three to 15 years of follow-up medical records available for analysis, including information on whether they had relapsed.

To identify the problematic cells from among the millions of cells in each sample, the researchers had to figure out how to organize the data. "Every patient has vastly different features to their cancer, and we had to ask, 'Is there any common thread between them?'" Davis said.

The solution, the team found, was to compare leukemic cells to their most similar normal cells along the trajectory of healthy B-cell development. Of 15 developmental cell stages examined, malignant cells arising from just two adjacent stages in B-cell maturation—the pro-B2 and pre-B1 stages—were the bad actors: If these particular types of malignant cells had certain signaling behavior at diagnosis, patients were almost certain to relapse after standard chemotherapy.

"Stem cell biology is evolving, and we've learned a lot about how normal development takes place," Good said. "Now we can use that to understand cancer better."

Combining methods gets better results

When the new method for predicting relapse was combined with existing methods based on patients' early response to treatment, the results were better than those obtained by either method alone.

"We do not understand the mechanisms by which from the pro-B2 and pre-B1 stages of development resist treatment," Davis said, adding that the team has begun looking for existing drugs to target them.

They plan to validate their method in a larger number of patients and to evaluate whether the same general approach could predict relapse in other forms of . Further, since the method provides information about treatment-resistant cells, patients found to be at high risk for relapse could benefit from treatments specific to those .

"We think that being more precise in risk prediction could benefit at both low and high risk for relapse," Davis said.

The study is an example of Stanford Medicine's focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.

Explore further: Stem-cell researchers solve mystery of relapse in acute myeloid leukemia

More information: Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse, Nature Medicine (2018). nature.com/articles/doi:10.1038/nm.4505

Related Stories

Stem-cell researchers solve mystery of relapse in acute myeloid leukemia

June 28, 2017
Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Common mutation is culprit in acute leukemia relapse

March 6, 2014
Harvard stem cell scientists have identified a mutation in human cases of acute lymphoblastic leukemia that likely drives relapse. The research, published in Cancer Cell, could translate into improved patient care strategies ...

Missing DNA fragments hold clue to predicting childhood leukaemia relapse

December 1, 2017
Australian researchers have developed a new risk scoring system for children with leukaemia based on missing DNA fragments or 'microdeletions'. The risk score will allow doctors to better predict the chance of relapse of ...

Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia

October 25, 2017
Oct. 25, 2017 - Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia ...

Recommended for you

Fusion hybrids: A newly discovered population of tumor cells

September 24, 2018
In a recent study published in Science Advances, Charles E. Gast and co-workers detail the spontaneous process of cancer cell fusion with white blood cells to produce heterogenous hybrid clones in multiple biological systems, ...

Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse

September 24, 2018
Harnessing the immune system to treat cancer shows great promise in some patients, but for many, the response does not last long-term. In an effort to find out why, Fred Hutchinson Cancer Research Center scientists are using ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.